Clevelanddx
Cleveland, US · 1 known investors
Cleveland Diagnostics develops blood-based biomarker tests for cancer detection using its IsoClear platform, which measures structural protein differences to improve diagnostic clarity. The company's first product, IsoPSA, targets prostate cancer screening and aims to reduce unnecessary biopsies.
BiotechDigital HealthMedical Devices